Introduction

The Cistor 50 mg (Cisplatin) Injection is a high-dose platinum-based chemotherapy agent formulated for the first-line treatment of advanced lung cancer, head and neck cancer, ovarian carcinoma, bladder carcinoma, and testicular carcinoma. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in precision oncology solutions, and supplied by Onco Solution, a global provider of life-saving cancer therapies, Cistor 50 mg delivers intensified DNA disruption in cancer cells while synergizing with radiotherapy and other cytotoxic agents. Designed for patients requiring higher dosing flexibility, this injection balances efficacy with rigorous safety protocols to manage aggressive malignancies.

Key Benefits

• High-Dose Precision: 50 mg/vial formulation for optimized dosing in advanced or bulky tumors.
• Synergistic Potency: Enhances outcomes when combined with 5-fluorouracil, etoposide, or radiotherapy.
• Targeted Action: Disrupts DNA replication in rapidly dividing cancer cells, inducing apoptosis.

Indications

The Cistor 50 mg (Cisplatin) Injection is indicated for:

• First-line treatment of advanced lung cancer, head and neck cancer, and metastatic ovarian carcinoma.
• Advanced bladder carcinoma and testicular carcinoma management.

Pharmacology

• Mechanism of Action: Cisplatin binds covalently to DNA, forming cross-links that block replication and transcription, leading to cancer cell death.
• Synergy: Amplifies tumor suppression when paired with fluorouracil, cyclophosphamide, or radioprotectant WR 2721.

Dosage & Administration

Metastatic Ovarian Cancer

• Monotherapy: 100 mg/m² infused in 0.9% sodium chloride or glucose once every 4 weeks (2 vials of 50 mg).
• Combination Therapy (with cyclophosphamide): 75–100 mg/m² on day 1 of a 4-week cycle.

Metastatic Testicular Tumors

• Dose: 20 mg/m² daily for 5 days per cycle (1 vial daily).

Advanced Bladder Cancer

• Initial Dose: 50–70 mg/m² every 3–4 weeks (adjust based on prior treatment exposure).
• Heavily Pre-Treated Patients: Start with 50 mg/m² every 4 weeks (1 vial).

General Dosing Guidelines

• Adults & Children: 50–100 mg/m² as a single agent.
• Common Schedules:
  • 40–120 mg/m² IV on day 1 every 3 weeks.
  • 15–20 mg/m² IV on days 1–5 every 3–4 weeks.

Drug Interactions

• Synergistic Partners: 5-fluorouracil, etoposide, and radioprotectant WR 2721.
• Avoid: Concurrent use with nephrotoxic agents (e.g., aminoglycosides, NSAIDs).

Contraindications

• Severe renal impairment (creatinine clearance < 60 mL/min).
• Pre-existing myelosuppression, hearing loss, or hypersensitivity to platinum compounds.

Side EffectsCommon Adverse Reactions:

• Severe Nausea/Vomiting: Mandatory antiemetic premedication required.
• Nephrotoxicity: Elevated creatinine, hypomagnesemia, hypocalcemia.
• Ototoxicity: Tinnitus, hearing loss (irreversible in children).

Serious Risks:

• Bone Marrow Suppression: Anemia, thrombocytopenia (rare at ≤100 mg doses).
• Neurotoxicity: Peripheral neuropathy, seizures, optic neuritis.
• Hypersensitivity Reactions: Anaphylaxis, bronchospasm (premedicate with corticosteroids).

Pregnancy & Lactation

• Pregnancy Category D: Contraindicated except in life-threatening scenarios. Use effective contraception during and 6 months post-treatment.
• Lactation: Discontinue breastfeeding due to risk of infant toxicity.

Precautions & Warnings

1. Hydration Protocol:
   • Administer 2 liters of IV fluid (0.9% saline or 5% glucose) pre- and post-infusion to reduce nephrotoxicity.
   • Maintain diuresis for 24 hours post-administration.
2. Monitoring:
   • Renal: Serum creatinine, BUN, electrolytes.
   • Auditory: Baseline and periodic hearing tests.
   • Hematologic: Regular CBC counts.

Overdose Management

Acute overdose may result in renal/hepatic failure, deafness, or fatal myelosuppression.
Treatment:

• Immediate hydration, forced diuresis, and electrolyte correction.
• Supportive care for seizures, neuropathy, and vomiting.

Reconstitution & Administration

• 50 mg Vial: Reconstitute with 50 ml sterile water for injection.
• Infusion Protocol: Dilute reconstituted solution in 2 liters of 5% glucose or 0.9% saline. Administer IV over 6–8 hours.
• Post-Infusion Care: Ensure adequate hydration and diuresis for 24 hours.

Storage Conditions

• Unopened Vial: Store at 25°C; protect from light.
• Reconstituted Solution:
  • Stable for 28 days if protected from light.
  • Stable for 7 days under fluorescent room light.

Why Choose Cistor 50 mg (Cisplatin) Injection?

• High-Dose Flexibility: Ideal for patients requiring intensified regimens or larger body surface areas.
• Trusted Quality: Produced by Eskayef Pharmaceuticals Ltd., a pioneer with 30+ years in oncology innovation.
• Global Reach: Supplied by Onco Solution, ensuring affordable access across Asia, Africa, and Europe.

Technical Specifications

• Active Ingredient: Cisplatin (50 mg/vial).
• Packaging: Lyophilized powder in sterile, tamper-evident vials.
• Shelf Life: 24 months (unopened).

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, merges cutting-edge research with uncompromising quality standards. Partnering with Onco Solution, they deliver equitable access to life-saving therapies, prioritizing patient outcomes in underserved regions.

Conclusion

The Cistor 50 mg (Cisplatin) Injection is a cornerstone of advanced cancer care, offering potent DNA-targeted action for aggressive malignancies. By integrating this high-dose therapy, clinicians leverage a trusted solution backed by Eskayef Pharmaceuticals Ltd. and Onco Solution – leaders in global oncology innovation.